ENOS NEWS

The Newsletter for the Efficacy of Nitric Oxide in Stroke Trial

ISSUE 4 FEBRUARY 2002

WEBSITE NOW FULLY ONLINE

he ENOS acrony m stands for "Efficacy of Nitric Oxide in Stroke". This study is a collaborative, international, multicentre, prospective, randomised, open, blinded-endpoint, parallel group, controlled, trial investigating the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping prior antihy pertensive therapy, in patients with acute ischaemic or haemorrhagic stroke.

THE WEBSITE

After some delay we are pleased announce that the ENOS trial website is now fully online. This will provide a convenient means of randomising patients, submitting report forms, adverse event reports, and downloading the trial documents. Access is available using any standard web browser. Not only does this make ENOS easy to participate in, but it also allows for 'real time' validation of the entered data. Security has been a major priority for our software development team to protect the data base. Access to the trial server is restricted to specific investigators at local centres identified by individual usernames, passwords and pin numbers. Security checks are also made on each individual computer that logs in and data exchange between the server and local computer is encry pted (128 bit).

If you would like to try the website out and see how easy it is to use then you are welcome to look at the practice (or example) database. This is available to anyone with internet access. In order to visit this site, www.nottingham.ac.uk/strokemedicine/enosindex.htm into v our browser and select 'enter example database'. To login you must enter the username 'nxnaksh', password 'xmskwlz' and pin 5328. Please note that these words must be entered in small letters otherwise access will be denied. Feel free to enter imaginary data and submit this by entering the pin number 5328 at the end of each form. As always, your comments on the website will be much appreciated and will influence later versions of the software.

TRIAL PROGRESS

Congratulations to our second participating centre in Singapore which has now randomised its second patient into the ENOS trial. In addition, another UK centre at Glan Clwyd Hospital has recently obtained local ethics approval for ENOS. We welcome other interested sites to fax, email or post the form which is attached with this newsletter to the ENOS trial office (addresses below). Alternatively, you can access this form at the ENOS trial website.

ENOS RECRUITMENT

NOTTINGHAM CITY HOSPITAL 19 PATIENTS SINGAPORE GENERAL HOSPITAL 2 PATIENTS